



## **TRICALS MAGNET platform trial**

### **Lithium carbonate in pALS with UNC13A variation**

The MAGNET study is an innovative clinical research platform investigating multiple potential ALS medicines simultaneously. This approach will significantly enhance the number of patients that can participate. Besides, the burden of participants is minimised while the chance of finding effective ALS medicines is maximised.

The first arm of the MAGNET study has started, studying lithium carbonate in ALS-patients with an UNC13A variation.

All information on the study can be found [here at the TRICALS website](#).

#### **EUpALS**

Vaartkom 17, B-3000 Leuven, Belgium

Tel: +32 (0)16-23 95 82 – Fax: +32 (0)16-29 98 65

[info@ALS.eu](mailto:info@ALS.eu) – [ALS.eu](http://ALS.eu)